Cell & Gene Therapy Manufacturing Services Market by Type (Cell Therapy, Gene Therapy), Indication (Cardiovascular Diseases, Central Nervous System Disorders, Infectious Diseases), Application, End-User - Global Forecast 2024-2030

Cell & Gene Therapy Manufacturing Services Market by Type (Cell Therapy, Gene Therapy), Indication (Cardiovascular Diseases, Central Nervous System Disorders, Infectious Diseases), Application, End-User - Global Forecast 2024-2030

The Cell & Gene Therapy Manufacturing Services Market size was estimated at USD 17.34 billion in 2023 and expected to reach USD 19.98 billion in 2024, at a CAGR 15.81% to reach USD 48.45 billion by 2030.

Cell and gene therapy manufacturing services encompass the specialized production processes required for the development and commercialization of cell and gene therapies. The scope of these services includes a comprehensive array of production activities such as the sourcing of raw materials, cell processing, gene transfection or vector integration, culturing, harvesting, purification, quality control, and final product formulation. As cell and gene therapies are widely considered a critical component in modern therapeutic development, the importance of robust, compliant, and scalable manufacturing capabilities becomes critical. The cell and gene therapy manufacturing services market is rapidly expanding, with the increasing prevalence of genetic disorders and cancers, advances in molecular biology, and significant investments from both the public and private healthcare sectors. Collaboration between academic institutions, biotech firms, and service providers further propels the market growth. Despite the growth, the market faces several challenges, including high costs of production, stringent and evolving regulatory requirements, and the complexity of manufacturing processes. The necessity for specialized facilities and skilled personnel increases operational challenges, and ensuring consistent quality and scalability remains a significant hurdle. However, the market is ripe with opportunities, particularly in the development of automation and closed-system manufacturing to improve efficiency and reduce contamination risks. Breakthroughs in cell and gene therapy are promising for personalized medicine, thus creating lucrative opportunities for specialized cell and gene therapy manufacturing services.

Regional Insights

In the Americas, the market for cell and gene therapy manufacturing services is experiencing robust growth. This upsurge is primarily driven by a well-established biotech ecosystem, substantial investments in research and development, and a favorable regulatory environment. Moreover, the presence of established market players and the high adoption rate of advanced therapies are catalyzing the market in America. The EMEA region is witnessing a significant expansion in the cell and gene therapy manufacturing service market, with Europe being at the forefront. The growth in the European Union is supported by strong governmental support, advanced healthcare infrastructure, and increasing collaborations between academic and industrial sectors. The Middle East and Africa are also showing growth potential, with increasing investment in healthcare infrastructure and a growing interest in advanced therapeutic modalities. The Asia-Pacific region is a rapidly emerging market in cell and gene therapy manufacturing services, driven by growing healthcare expenditures and a rising number of local companies entering the space. Technological advancements and increasing partnerships with Western companies are further propelling the market forward in this region.

Market Insights

• Market Dynamics
  
  The market dynamics represent an ever-changing landscape of the Cell & Gene Therapy Manufacturing Services Market by providing actionable insights into factors, including supply and demand levels. Accounting for these factors helps design strategies, make investments, and formulate developments to capitalize on future opportunities. In addition, these factors assist in avoiding potential pitfalls related to political, geographical, technical, social, and economic conditions, highlighting consumer behaviors and influencing manufacturing costs and purchasing decisions.
  • Market Drivers
    • High Incidence of Cancer and Other Target Diseases
    • Increasing Investments in Pharmaceutical R&D and Advanced Technologies by CDMOs
    • Focus on the Personalized Medicine with the Rising Tendency Towards Early Disease Diagnosis
    • Market Restraints
      • High Operational Costs Associated With Cell & Gene Therapy Manufacturing Services
      • Market Opportunities
        • Emergence of Advanced Analytical Technologies in Development of Cell & Gene Therapy
        • Improvement in the Supply Chain of Cell & Gene Therapy Manufacturing
        • Market Challenges
          • Quality Control and Contamination Issues in Cell & Gene Therapy Production
          • Market Segmentation Analysis
            • Type: Applications of autologous mesenchymal stem cells for tissue repair and anti-inflammatory treatments
            • Indication: Growing potential of oncology therapies for personalized medicine in patients with various malignancies
            • Application: Significant benefits of customized cell & gene therapy manufacturing services for early-stage products
            • End-User: Higher preferences for cost-effective services from academic and research institutes
            • Market Disruption Analysis
            • Porter’s Five Forces Analysis
            • Value Chain & Critical Path Analysis
            • Pricing Analysis
            • Technology Analysis
            • Patent Analysis
            • Trade Analysis
            • Regulatory Framework Analysis
            FPNV Positioning Matrix
            
            The FPNV positioning matrix is essential in evaluating the market positioning of the vendors in the Cell & Gene Therapy Manufacturing Services Market. This matrix offers a comprehensive assessment of vendors, examining critical metrics related to business strategy and product satisfaction. This in-depth assessment empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success, namely Forefront (F), Pathfinder (P), Niche (N), or Vital (V).
            
            Market Share Analysis
            
            The market share analysis is a comprehensive tool that provides an insightful and in-depth assessment of the current state of vendors in the Cell & Gene Therapy Manufacturing Services Market. By meticulously comparing and analyzing vendor contributions, companies are offered a greater understanding of their performance and the challenges they face when competing for market share. These contributions include overall revenue, customer base, and other vital metrics. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With these illustrative details, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.
            
            Recent Developments
            • Fujifilm to Invest USD 200 Million to Expand
              
              FUJIFILM Corporation announces a strategic investment of USD 200 million to enhance its cell therapy contract development and manufacturing (CDMO) services, responding to the rapidly growing market. This funding is allocated to two principal subsidiaries, FUJIFILM Cellular Dynamics, Inc. and FUJIFILM Diosynth Biotechnologies.
              
              eXmoor Pharma Expands into Full-Service Cell and Gene Therapy CDMO Partner with Opening of GMP Facilities
              
              eXmoor Pharma announced the inauguration of its state-of-the-art cell and gene therapy center, located in Bristol, which is purpose-built to facilitate the scaling of next-generation CGTs, advancing them from clinical trials to patient reach. Equipped with four expansive grade C processing modules, the facility boasts a process-agnostic architecture suitable for various CGT productions, complete module segregation, and substantial bioreactor capacity. This encompasses options such as two 200L systems for viral vectors or allogeneic therapies and accommodation for five autologous cell therapy stations.
              
              Thermo Fisher Scientific Opens Cell Therapy Facility at UCSF to Accelerate Development of Breakthrough Therapies
              
              Thermo Fisher Scientific Inc., alongside the University of California, San Francisco (UCSF), has embarked on an ambitious endeavor to expedite the development of advanced cell therapies. This collaboration is facilitated by the strategic positioning of their state-of-the-art cGMP facility, which is stationed in close proximity to the UCSF Medical Center at Mission Bay. Offering comprehensive services from process and analytical development to clinical and commercial production, Thermo Fisher and UCSF aim to trailblaze advancements in the treatment of diseases, even extending to autoimmune disorders.
            Strategy Analysis & Recommendation
            
            The strategic analysis is essential for organizations seeking a solid foothold in the global marketplace. Companies are better positioned to make informed decisions that align with their long-term aspirations by thoroughly evaluating their current standing in the Cell & Gene Therapy Manufacturing Services Market. This critical assessment involves a thorough analysis of the organization’s resources, capabilities, and overall performance to identify its core strengths and areas for improvement.
            
            Key Company Profiles
            
            The report delves into recent significant developments in the Cell & Gene Therapy Manufacturing Services Market, highlighting leading vendors and their innovative profiles. These include Advanced BioScience Laboratories, Inc., AGC Biologics, Bio-Techne Corporation, Bluebird Bio, Inc., Boehringer Ingelheim International GmbH, c-LEcta GmbH, Catalent, Inc., Cell and Gene Therapy Catapult, Cell Therapies Pty Ltd., Cell-Easy SAS, Charles River Laboratories International, Inc., Exmoor Pharma Concepts Limited, F. Hoffmann-La Roche Ltd., FUJIFILM Diosynth Biotechnologies, General Electric Company, Lonza Group, Merck KGaA, Miltenyi Biotec B.V. & Co. KG, Minaris Regenerative Medicine GmbH, Nikon Corporation, Novartis AG, Oxford Biomedica PLC, Recipharm AB, Resonac Corporation, Samsung Biologics Co., Ltd, Takara Holdings Inc., Thermo Fisher Scientific, Inc., uBriGene Biosciences Inc., and Wuxi Apptec Co., Ltd..
            
            Market Segmentation & Coverage
            
            This research report categorizes the Cell & Gene Therapy Manufacturing Services Market to forecast the revenues and analyze trends in each of the following sub-markets:
            • Type
              • Cell Therapy
                • Allogeneic
                  • Allogeneic Hematopoietic Stem Cells
                  • Allogeneic Induced Pluripotent Stem Cells
                  • Allogeneic Mesenchymal Stem Cells
                  • Allogeneic Natural Killer Cells
                  • Allogeneic T-cells
                  • Autologous
                    • Autologous Hematopoietic Stem Cells
                    • Autologous Mesenchymal Stem Cells
                    • Autologous Natural Killer Cells
                    • Autologous T-cells
                    • Viral Vector
                      • Adeno-associated Virus Vectors
                      • Retroviral Vectors
                      • Gene Therapy
                        • Non-viral Vector
                        • Oligonucleotides
                        • Indication
                          • Cardiovascular Diseases
                          • Central Nervous System Disorders
                          • Infectious Diseases
                          • Oncology Diseases
                          • Ophthalmology Diseases
                          • Orthopedic Diseases
                          • Application
                            • Clinical Manufacturing
                            • Commercial Manufacturing
                            • End-User
                              • Academic & Research Institutes
                              • Pharmaceutical & Biotechnology Companies
                              • Region
                                • Americas
                                  • Argentina
                                  • Brazil
                                  • Canada
                                  • Mexico
                                  • United States
                                    • California
                                    • Florida
                                    • Illinois
                                    • New York
                                    • Ohio
                                    • Pennsylvania
                                    • Texas
                                    • Asia-Pacific
                                      • Australia
                                      • China
                                      • India
                                      • Indonesia
                                      • Japan
                                      • Malaysia
                                      • Philippines
                                      • Singapore
                                      • South Korea
                                      • Taiwan
                                      • Thailand
                                      • Vietnam
                                      • Europe, Middle East & Africa
                                        • Denmark
                                        • Egypt
                                        • Finland
                                        • France
                                        • Germany
                                        • Israel
                                        • Italy
                                        • Netherlands
                                        • Nigeria
                                        • Norway
                                        • Poland
                                        • Qatar
                                        • Russia
                                        • Saudi Arabia
                                        • South Africa
                                        • Spain
                                        • Sweden
                                        • Switzerland
                                        • Turkey
                                        • United Arab Emirates
                                        • United Kingdom
                                        
                                        
                                        Please Note: PDF & Excel + Online Access - 1 Year